SGHT

In the past six months, Sight Sciences' stock (SGHT) has increased by 144.67%. Key events include strong Q1 2026 financial results on May 6, 2026, reporting a 13% revenue increase and raised full-year guidance. On the same date, a U.S. District Court issued a final judgment in a patent infringement case against Alcon, awarding Sight Sciences $55.4 million in damages and an ongoing royalty. Q2 2026 financial results on August 5, 2026, showed a 20% revenue increase, further raised full-year guidance, and reduced operating expense guidance. On August 19, 2026, the FDA expanded the indications for the TearCare System, making it the first and only MGD treatment cleared to improve meibomian gland function. Additionally, Kashif Rashid was appointed as Chief Legal Officer and Corporate Secretary on August 10, 2026.